Next-Gen Drug Delivery: Rethinking Routes for New Therapies

Drug Delivery Leader Chief Editor Tom von Gunden and Executive Editor Fran DeGrazio engaged drug delivery innovation experts James Wabby and Carolyn Dorgan in a discussion of technology innovations and regulatory pathways for combination products, combination therapies, and other advances in targeted, personalized medicines. Illustrating their points with the example of antibody-drug conjugates (ADCs), the panelists offered specific recommendations for organizational and regulatory readiness for biopharmaceutical companies moving into drug-device, drug-biologic, and biologic-biologic combination therapy development.